Intensity Therapeutics (INTS) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Intensity Therapeutics (INTS) has outperformed Passage Bio (PASG) over the past year, losing 48.4% versus a loss of 54.3%. Passage Bio is the larger company by market cap ($12.2 million vs $12.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INTS | PASG |
|---|---|---|
| Share price | $3.68 | $3.78 |
| Market cap | $12.01M | $12.16M |
| 1-day change | -3.16% | -1.95% |
| YTD return | -64.10% | -67.97% |
| 1-year return | -48.35% | -54.35% |
| 5-year return | — | -98.06% |
| EPS (TTM) | $-3.89 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.50 | $20.00 |
| 52-week low | $3.21 | $3.29 |
| Distance from 52-week high | -91.54% | -81.10% |
| Analyst consensus | none | buy |
| Avg. price target upside | +425.27% | +310.05% |
| Average volume | 25.93K | 26.11K |
| Shares outstanding | 3.26M | 3.22M |
| Employees | 5 | 24 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Healthcare · Biotechnology · 5 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Healthcare · Biotechnology · 24 employees
INTS vs PASG FAQ
Which is bigger, Intensity Therapeutics or Passage Bio?
Passage Bio (PASG) is larger, with a market capitalization of $12.16M compared with $12.01M for Intensity Therapeutics (INTS).
Which stock has performed better over the past year, INTS or PASG?
INTS returned -48.35% over the past 12 months, compared with -54.35% for PASG (price return, excluding dividends). Past performance does not predict future results.
Are Intensity Therapeutics and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.